Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease

European Journal of Neurology

Volumn 14, Issue 2, 2007, Pages 156-161

  Vilar, R ^a   Coelho, H ^b   Rodrigues, E ^a   Gama, M J ^a   Rivera, I ^a   Taioli, E ^c   Lechner, M C ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

CYP2D6; Dopaminergic neurodegeneration; Drug metabolizing enzymes; Genetic polymorphism; Genetic risk assessment; GSTM1; GSTP1; Parkinson's disease

Indexed keywords

ADENINE NUCLEOTIDE; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GUANINE NUCLEOTIDE;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GERIATRIC PATIENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADENINE; AGED; AGED, 80 AND OVER; ALLELES; CYTOCHROME P-450 CYP2D6; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; GUANINE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MIDDLE AGED; PARKINSON DISEASE; PHENOTYPE; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 33846433663     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01590.x     Document Type: Article

References (35)

1. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Annals of Neurology 1998; 44: S72-84.
2. Grunblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. Journal of Neural Transmission 2004; 111: 1543-1573.
3. Zhang Y, James M, Middleton FA, Davis RL. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2005; 137: 5-16.
4. Hauser MA, Li YJ, Xu H, et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Archives of Neurology 2005; 62: 917-921.
5. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
6. Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. Journal of Neuropathology and Experimental Neurology 1997; 56: 125-131.
7. Burdon RH. Thermotolerance and the heat shock proteins. Symposia of the Society for Experimental Biology 1987; 41: 269-283.
8. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001; 29: 15-32.
9. Nicotera P. Molecular switches deciding the death of injured neurons. Toxicological Sciences 2003; 74: 4-9.
10. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism and Related Disorders 2002; 8: 297-309.
11. Strange RC, Fryer AA, Matharoo B, et al. The human glutathione S-transferases: comparison of isoenzyme expression in normal and astrocytoma brain. Biochimica et Biophysica Acta 1992; 1139: 222-228.
12. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochemical Journal 1997; 324: 25-28.
13. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M. Cellular localization and regional distribution of CY-P2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001; 11: 237-245.
14. Hayes JD, Flanagan JU, Jowsey IR. Glutathione Transferases. Annual Review of Pharmacology and Toxicology 2005; 45: 51-88.
15. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proceedings of the National Academy of Sciences of the U S A 1988; 85: 7293-7297.
16. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiology, Biomarkers and Prevention 2001; 10: 1239-1248.
17. Stroombergen MC, Waring RH. Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Human Experimental Toxicology 1999; 18: 141-145.
18. Ahmadi A, Fredrikson M, Jerregard H, et al. GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. Biochemical and Biophysical Research Communications 2000; 269: 676-680.
19. Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochemical and Biophysical Research Communications 2001; 288: 887-892.
20. Tison F, Coutelle C, Henry P, Cassaigne A. Glutathion S-transferase (class mu) phenotype in Parkinson's disease. Movement Disorders 1994; 9: 117-118.
21. Xia C, Hu J, Ketterer B, Taylor JB. The organization of the human GSTP1-1 gene promoter and its response to retinoic acid and cellular redox status. Biochemical Journal 1996; 313: 155-161.
22. Adler V, Yin Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp. EMBO Journal 1999; 18: 1321-1334.
23. Meriin AB, Yaglom JA, Gabai VL, et al. Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72. Molecular and Cellular Biology 1999; 19: 2547-2555.
24. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998; 352: 1344-1346.
25. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedeberg's Archives of Pharmacology 2004; 369: 23-37.
26. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry 1992; 55: 181-184.
27. Smith CA, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-1377.
28. Zhong S, Howie AF, Ketterer B, et al. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991; 12: 1533-1537.
29. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18: 641-644.
30. Zuntar I, Kalanj-Bognar S, Topic E, Petlevsi R, Stefanovic M, Demarin V. The glutathione S-transferase polymorphisms in a control population and in Alzheimer's disease patients. Clinical Chemistry and Laboratory Medicine 2004; 42: 334-339.
31. Elbaz A, Levecque C, Clavel J, et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Annals of Neurology 2004; 55: 430-434.
32. Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Annals of Neurology 2004; 55: 897.
33. Kelada SN, Stapleton PL, Farin FM, et al. Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson's disease. Neuroscience Letters 2003; 337: 5-8.
34. Gabai VL, Meriin AB, Mosser DD, et al. Hsp70 prevents activation of stress kinases. A novel pathway of cellular thermotolerance. Journal of Biological Chemistry 1997; 272: 18033-18037.
35. Yaglom JA, Gabai VL, Meriin AB, Mosser DD, Sherman MY. The function of HSP72 in suppression of c-Jun N-terminal kinase activation can be dissociated from its role in prevention of protein damage. Journal of Biological Chemistry 1999; 274: 20223-20228.